The pivotal role of lipoprotein lipase in atherosclerosis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Time for primary review 33 days. Atherosclerosis, the underlying cause of heart attacks, stroke and peripheral vascular disease, is responsible for over 50% of all deaths in developed countries. The disease can generally be viewed as a form of chronic inflammation that is induced and perturbed by lipid accumulation and involves a number of components, including the damaged endothelium, monocytes/macrophages, T cells, smooth muscle cells and a regulatory network of growth factors and cytokines (see Refs. [1,2] for reviews). The process is believed to be triggered by damage to the arterial endothelial cells leading to dramatic changes in their properties and increased expression of both chemokines and adhesion molecules [1,2]. This causes an infiltration of both T lymphocytes and monocytes to the site of damage. The monocytes then differentiate into macrophages, internalise lipoproteins, and transform into lipid-loaded foam cells to form the fatty streak seen in early lesions [1,2]. This transformation of macrophages into foam cells represents a critical initial event in the pathogenesis of atherosclerosis. It is, therefore, not surprising that a major focus in cardiovascular research has been devoted to understanding the molecular basis of foam cell formation and has resulted in the identification of a key, but complex, role of the enzyme lipoprotein lipase (LPL; EC 3.1.1.34) in the process. LPL is a central enzyme in overall lipid metabolism and transport, being responsible for catalysing the hydrolysis of triglycerides transported in the bloodstream by chylomicrons and VLDL, thereby providing non-esterified fatty acids and 2-monoacylglycerols for tissue utilization [3,4]. Due to the large size of its substrates, the physiological site of LPL action is at the luminal surface of blood vessels, to which the enzyme is attached via highly charged heparan sulphate proteoglycans (HSPG) [3,4]. Mature LPL is secreted to the vascular endothelium from the parenchymal cells of the adipose and muscle tissues, its major sites of synthesis, and a variety of other tissues which have also been implicated as lesser, but significant, sources of the enzyme [3,4]. Of these alternative sources, studies on LPL expressed by cell types found in the locus of the vascular wall, particularly by monocyte-derived macrophages, have identified additional, pathophysiological actions of the enzyme that promote foam cell formation and, ultimately, atherosclerosis. In direct contrast to this, LPL produced by adipose tissue and muscle has a protective effect with respect to atherosclerosis. As a result of these observations, LPL has been identified as a potential therapeutic target and continues to be the subject of extensive scientific investigation. In this comprehensive and current review, the most recent evidence implicating LPL in both its pro- and anti-atherogenic roles will be discussed. In addition, data regarding the regulation of the enzyme by factors involved in atherosclerosis will be covered. The importance of LPL in the atherosclerotic process was first proposed in 1973 by Donald Zilversmit [5]. He postulated that the action of LPL on circulating VLDL and chylomicrons would lead to high, localized concentrations of cholesterol-rich remnants, which would subsequently be taken up into the arterial wall and propagate lesion formation. Since this hypothesis was formulated, it has been shown to be true but, as this article will discuss, is far more complex than originally anticipated. Of the cell types present in the atherosclerotic lesion, LPL is known to be expressed by both monocyte-derived macrophages and smooth muscle cells [3,4]. The differentiation of monocytes to macrophages is accompanied by a substantial increase in LPL mRNA, protein and activity levels [6] and has also recently been shown to lead to an increase in the level of apolipoprotein C-II [7], a known activator of LPL [3]. These macrophages transform into foam cells through the accumulation of lipids [1,2]. Detailed immunocytochemical and in situ hybridization experiments have shown that it is the macrophage-derived foam cells, and not smooth muscle cells, that are the primary source of LPL in the lesion [8]. In addition, the expression of LPL mRNA, protein and enzymatic activity have all been found to increase in response to damage sustained by the arterial wall [9,10]. Vascular injury has long been known to be a precursor of clinical conditions associated with atherosclerosis and is, indeed, how the well-established ‘response to injury’ hypothesis for atherogenesis was derived [1,2]. The possibility that variations in macrophage LPL synthesis and secretion might constitute a hereditary component of atherosclerosis was investigated by Renier and colleagues [11] who evaluated LPL levels in macrophages from inbred mouse strains differing in their susceptibility to diet-induced atherosclerosis. It was observed that macrophages isolated from mice susceptible to athero
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Bellosta, S., Mahley, R. W., Sanan, D. A., Murata, J., Newland, D. L., Taylor, J. M., & Pitas, R. E. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118271 · Cited by 284
Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis
Clee, S. M., Bissada, N., Miao, F., Miao, L., Marais, A. D., Henderson, H. E., Steures, P., McManus, J., McManus, B., LeBoeuf, R. C., et al. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32399-3 · Cited by 101
Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase Activity
Davies, P. J. A., Berry, S. A., Shipley, G. L., Eckel, R. H., Hennuyer, N., Crombie, D. L., Ogilvie, K. M., Peinado-Onsurbe, J., Fievet, C., Leibowitz, M. D., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.2.170 · Cited by 89
Cited by
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Self-citationThe macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427
McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.04.002 · Cited by 397
Metadata
- Authors
- Mead, J.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-08-01
- Volume
- 55
- Issue
- 2
- Pages
- 261-269
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2037777940
- Cited by
- 106
- References
- 5
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pivotal role of lipoprotein lipase in atherosclerosis. https://app.cochat.ai/papers/10.1016/s0008-6363(02)00405-4
- The paper
- Mead, J. (2002). The pivotal role of lipoprotein lipase in atherosclerosis. Cardiovascular Research. https://doi.org/10.1016/s0008-6363(02)00405-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.